Table 1.
Patient demographic, disease and clinical characteristics
| Patient characteristic | n(%) |
|---|---|
| Total | 377a |
| Age in years, mean(SD), y | 61 (13) |
| Race/ethnicity | |
| White | 262 (69) |
| Chinese origin | 48 (13) |
| Black/African-American | 40 (11) |
| Hispanic/Latino | 11 (3) |
| Others | 14 (4) |
| Language | |
| English | 321 (85) |
| All others | 56 (15) |
| Census tract median household income, median (25th, 75th percentiles),$ | 71,367 (57,360 – 92,093) |
| Insurance | |
| Private only | 153 (41) |
| Any subsidizedb | 211 (56) |
| Married / Partnered | 211 (56) |
| Tumor stage | |
| I | 216 (57) |
| II | 98 (26) |
| III | 42 (11) |
| IV | 21 (6) |
| HER2-positive | 45 (12) |
| ER- and/or PR-positive | 315 (84) |
| Triple-negative | 45 (12) |
| Had multiple biopsies | 53 (14) |
| Had family history of breast cancer | 164 (44) |
| Had prior history of breast cancer treatment | 35 (9) |
| Had any comorbidity (Charlson score 1–8) | 131 (35) |
| Modality of first treatment | |
| No initiation of treatment | 10 (3) |
| Neoadjuvant chemotherapy | 34 (9) |
| Surgery | 322 (85) |
| Hormone therapy | 10 (3) |
Abbreviations: ER = estrogen receptor; HER2 = human epidermal growth factor receptor 2; PR = progesterone receptor; SD = standard deviation.
a
All newly diagnosed stage I to IV breast cancer patients presented at Tufts MC from 2009 through 2015.
b
”Any subsidized” includes any Medicare, MassHealth (MA Medicaid), and/or any health insurance exchange product.